Appili Therapeutics Inc
TSX:APLI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Appili Therapeutics Inc
Current Portion of Long-Term Debt
Appili Therapeutics Inc
Current Portion of Long-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Current Portion of Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Appili Therapeutics Inc
TSX:APLI
|
Current Portion of Long-Term Debt
CA$11.6m
|
CAGR 3-Years
387%
|
CAGR 5-Years
197%
|
CAGR 10-Years
N/A
|
|
|
Bausch Health Companies Inc
TSX:BHC
|
Current Portion of Long-Term Debt
$236m
|
CAGR 3-Years
-18%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-12%
|
|
|
Canopy Growth Corp
TSX:WEED
|
Current Portion of Long-Term Debt
CA$12.9m
|
CAGR 3-Years
-70%
|
CAGR 5-Years
-24%
|
CAGR 10-Years
41%
|
|
|
Cronos Group Inc
TSX:CRON
|
Current Portion of Long-Term Debt
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Mind Medicine (MindMed) Inc
NASDAQ:MNMD
|
Current Portion of Long-Term Debt
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
K
|
Knight Therapeutics Inc
TSX:GUD
|
Current Portion of Long-Term Debt
CA$20.1m
|
CAGR 3-Years
0%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
N/A
|
|
Appili Therapeutics Inc
Glance View
Appili Therapeutics, Inc. is a pharmaceutical company, which acquires and develops novel treatments targeting unmet needs in infectious disease. The company is headquartered in Halifax, Nova Scotia. The company went IPO on 2019-06-25. The firm is focused on the acquisition and development of medicines targeting infectious disease. The firm also focused on building and advancing a diverse portfolio of anti-infective programs. Its anti-infective portfolio includes ATI-2307, ATI-1701, ATI-1503, ATI-1501 and Favipiravir. The ATI-2307 is used for the treatment of invasive fungal infections with a near-term focus on those caused by Cryptococcus and Candida. The ATI-1701 is a live-attenuated vaccine for Francisella tularensis. The ATI-1503 is a drug discovery program builds off the molecular structure of negamycin, a naturally occurring compound that can kill Gram-negative bacteria. The ATI-1501 is a taste-masked liquid oral suspension formulation of the antibiotic metronidazole. Metronidazole is a front-line antibiotic for the treatment of anaerobic bacterial and parasitic infections. The Favipiravir is an oral covid-19 antiviral candidate.
See Also
What is Appili Therapeutics Inc's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
11.6m
CAD
Based on the financial report for Mar 31, 2025, Appili Therapeutics Inc's Current Portion of Long-Term Debt amounts to 11.6m CAD.
What is Appili Therapeutics Inc's Current Portion of Long-Term Debt growth rate?
Current Portion of Long-Term Debt CAGR 5Y
197%
Over the last year, the Current Portion of Long-Term Debt growth was 58%. The average annual Current Portion of Long-Term Debt growth rates for Appili Therapeutics Inc have been 387% over the past three years , 197% over the past five years .
